Caliway Biopharmaceuticals Future Growth
Future criteria checks 5/6
Caliway Biopharmaceuticals is forecast to grow earnings and revenue by 182.1% and 242.7% per annum respectively while EPS is expected to grow by 181.8% per annum.
Key information
182.1%
Earnings growth rate
181.8%
EPS growth rate
| Pharmaceuticals earnings growth | 59.1% |
| Revenue growth rate | 242.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 18 Oct 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 2,288 | 1,121 | 3,087 | 1,176 | 2 |
| 12/31/2024 | 37 | -796 | -773 | -735 | 2 |
| 9/30/2024 | 50 | -651 | -617 | -603 | N/A |
| 6/30/2024 | 36 | -622 | -566 | -550 | N/A |
| 3/31/2024 | 39 | -612 | -502 | -492 | N/A |
| 12/31/2023 | 39 | -488 | -434 | -424 | N/A |
| 9/30/2023 | 33 | -459 | -414 | -404 | N/A |
| 6/30/2023 | 28 | -429 | -395 | -384 | N/A |
| 3/31/2023 | 16 | -322 | -301 | -288 | N/A |
| 12/31/2022 | 13 | -286 | -257 | -243 | N/A |
| 9/30/2022 | 6 | -275 | -203 | -193 | N/A |
| 6/30/2022 | 0 | -263 | -149 | -143 | N/A |
| 3/31/2022 | 6 | -244 | -138 | -127 | N/A |
| 12/31/2021 | 12 | -224 | -126 | -111 | N/A |
| 12/31/2020 | 10 | -98 | -47 | -47 | N/A |
| 12/31/2019 | 19 | -122 | -107 | -107 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6919 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: 6919 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6919 is expected to become profitable in the next 3 years.
Revenue vs Market: 6919's revenue (242.7% per year) is forecast to grow faster than the TW market (12.7% per year).
High Growth Revenue: 6919's revenue (242.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6919's Return on Equity is forecast to be high in 3 years time